Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.

Authors:
Address: Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. kbaggehansen@dadlnet.dk
Journal:


Publication:

abstract

OBJECTIVE:

The insulinotropic effect of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) is Impaired in patients with type 2 diabetes. It remains unclear whether this impairment is a primary pathophysiological trait or a consequence of developing diabetes. Therefore, we aimed to investigate the insulinotropic effect of GIP and GLP-1 compared with placebo before and after 12 d of glucose homeostatic dysregulation in healthy subjects.

RESEARCH DESIGN AND METHODS:

The insulinotropic effect was measured using hyperglycemic clamps and infusion of physiological doses of GIP, GLP-1, or saline in 10 healthy Caucasian males before and after intervention using a high-calorie diet, sedentary lifestyle, and administration of prednisolone (37.5 mg once daily) for 12 d.

RESULTS:

The intervention resulted in increased insulin resistance according to the homeostatic model assessment (1.2 ± 0.2 vs. 2.6 ± 0.5, P = 0.01), and glucose tolerance deteriorated as assessed by the area under curve for plasma glucose during a 75-g oral glucose tolerance test (730 ± 30 vs. 846 ± 57 mm for 2 h, P = 0.021). The subjects compensated for the change in insulin resistance by significantly increasing their postintervention insulin responses during saline infusion by 2.9 ± 0.5-fold (P = 0.001) but were unable to do so in response to incretin hormones (which caused insignificant increases of only 1.78 ± 0.3 and 1.38 ± 0.3-fold, P value not significant).

CONCLUSIONS:

These data show that impairment of the insulinotropic effect of both GIP and GLP-1 can be induced in healthy male subjects without risk factors for type 2 diabetes, indicating that the reduced insulinotropic effect of the incretin hormones observed in type 2 diabetes most likely is a consequence of insulin resistance and glucose intolerance rather than a primary event causing the disease.



Related Articles
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.
J Clin Endocrinol Metab. 2010
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.
Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. J Clin Endocrinol Metab. 2010 Jul; 95(7):3309-17. Epub 2010 Apr 21.
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
J Clin Endocrinol Metab. 2003
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. J Clin Endocrinol Metab. 2003 Jun; 88(6):2706-13.
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Regul Pept. 2003
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Regul Pept. 2003 Jul 15; 114(2-3):115-21.
Review Incretin hormones and beta cell function in chronic pancreatitis.
Dan Med Bull. 2010
Review Incretin hormones and beta cell function in chronic pancreatitis.
Knop FK. Dan Med Bull. 2010 Jul; 57(7):B4163.
Review The incretin system and its role in type 2 diabetes mellitus.
Mol Cell Endocrinol. 2009
Review The incretin system and its role in type 2 diabetes mellitus.
Holst JJ, Vilsbøll T, Deacon CF. Mol Cell Endocrinol. 2009 Jan 15; 297(1-2):127-36. Epub 2008 Aug 20.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.